BRIEF-Nuvo Pharmaceuticals- Pennsaid trial to support regulatory approvals in E.U., Canada And Australia

Wed Jul 13, 2016 7:58am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 13 (Reuters) - Nuvo Pharmaceuticals Inc

* Topline results of trial are expected to be available in late Q2 or early Q3 2017

* Nuvo Pharmaceuticals Inc announces Pennsaid 2% phase 3 trial to support regulatory approvals in the E.U., Canada and Australia

* Nuvo Pharmaceuticals Inc says trial will cost approximately cdn$1.5 million spread over second half of 2016 and first half of 2017 Source text for Eikon: Further company coverage: